By Sandra Raymond, president and CEO, The Lupus Foundation of America
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
The Catalyst today welcomes The Lupus Foundation of America’s president and CEO Sandra Raymond to discuss advances in research for lupus.
At the Lupus Foundation of America (LFA), we are devoted to solving the mystery of lupus, which is a cruel, unpredictable and a devastating autoimmune disease that can damage any part of the body. Because of the toll that untreated lupus can have on the body, there is tremendous need for a range of treatment options, and yet currently there are only a handful of U.S. Food and Drug Administration approved therapies.
The current research pipeline broadly highlights what we in the lupus community are seeing in our disease area: diverse approaches to a tough scientific challenge. Our regulatory system must keep pace with the science and embrace the latest tools to improve the process to deliver these treatments to patients.
The LFA has devoted our work to finding a cure for a disease that impacts 1.5 million Americans. With the advancements in biopharmaceutical treatments, we believe we can find a cure for lupus, and for the other diseases currently thought of as incurable. LFA has made pioneering contributions towards ending the brutal impact of this unpredictable disease, including dedicated funding into the impact of lupus on the cardiovascular system, brain, and kidney.
A recent report from The Analysis Group shows that 74 percent of the medicines in the pipeline have the potential to be first-in-class therapies. Whereas in the past some lupus treatments have controlled the disease by suppressing the entire immune system, today, we are seeing more medicines in development that take a targeted approach. In addition, there are over 800 orphan drugs that are currently in clinical development across several rare disease states, including lupus. These discoveries require a better understanding of the underlying disease and a commitment to innovative research shared across the ecosystem.
To learn more about innovative therapies in the biopharmaceutical pipeline, click here. and learn more about lupus here.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
The Patient Perspective: Vaccines
New Report: Tackling chronic conditions with preventive treatment
New Report: Vaccines continue to drive improved health outcomes
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
New Report: 1,600 cancer treatments and vaccines in clinical development
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
Support for continued progress is critical for pediatric drug development
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
State policymakers can protect American innovation and help Americans live longer, healthier lives
Recognizing National Glaucoma Awareness Month
New Report More than 160 medicines in development for mental illness
ICYMI: Cancer death rate continues to decline due to treatment advances
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
New Report: Nearly 800 medicines in development to treat chronic conditions
Recognizing National Sickle Cell Awareness Month
Potential gene therapies bring hope to patients with sickle cell disease
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Report: More than 500 medicines in development to treat disorders of the blood
Report: More than 600 medicines in development for diseases affecting women
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
New Report: Nearly 800 new medicines in development to treat rare diseases
Guest post: Continued research and development is critical for ALS patients and families
New report shows more than 260 medicines in development to fight neurodegenerative diseases
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Report: More than 1,300 medicines and vaccines in development to help fight cancer
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
New report explores setbacks that bring future cancer success stories
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Nearly 400 cell and gene therapies in development to target a broad range of diseases
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Nearly 140 medicines in development to treat mental illness
New report finds 15 new oncology therapies launched last year
Guest Post: Using the patient voice to go boldly
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Event: New era of medicine comes to Capitol Hill
New report shows more than 160 medicines in development for diabetes and related conditions
Minority health matters
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
Putting 2018 medicine approvals in context
New report shows nearly 300 cell and gene therapies in development
World AIDS Day 2018: Hope for the future
New report shows more than 300 skin disease medicines in development
New report details the setbacks and challenges to Alzheimer’s research
Disrupting Alzheimer's
Aspen Spotlight Health: Discussing the forefront of innovation
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
A new era in Alzheimer’s innovation
New report shows over 500 medicines in development for neurological disorders
Guest post: Advancing healthy hearts for patients
Rare Disease Day: Unmet need inspires innovation
New report shows 200 medicines in development for heart disease and stroke
ICYMI: Why 2017 medicine approvals matter
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
New report and event examine the new era of vaccines
A new era in cancer
2017 Research & Hope Awards honor innovators in mental health
How biopharmaceutical collaboration is driving a new era of medicine
Medicare Monday: Strengthening access to vaccines for seniors
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
New report portrays flourishing pipeline
Going boldly together: New advancements and new anniversaries
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Examining the brain in The New Era of Medicine
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
More than 240 immuno-oncology treatments in development to fight cancer
A New World of Medicine: New GOBOLDLY ads showcase groundbreaking scientific advancements
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
ICYMI: New era of medicine initiative kicks off in Boston
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
VIDEO: PhRMA CEO joins CNBC’s Squawk on the Street to discuss industry campaign #GOBOLDLY
The 20-year journey yielding a new weapon against cancer
Significant progress fighting cancer: Death rate has dropped 25 percent
3 things to know about 2016 drug approvals
Finding cures for incurable diseases
Lupus
Medicines in Development
New Era of Medicine
Finding cures for incurable diseases
Finding cures for incurable diseases